Lactic acidosis (LA) and severe hyperlactataemia (HL) are infrequent but serious complications of antiretroviral therapy that have been associated with a high fatality rate.
Methods
In a multinational retrospective cohort study, LA was defined as arterial blood pH<7.35, bicarbonate <20 mmol/l and lactate above normal, and HL as con-firmed blood lactate >5 mmol/l. Logistic regression was used to identify factors associated with fatality. Sensitivity and specificity of different case definitions as predictors of death were compared.
Results
The overall case-fatality rate was 19/110 (17.3%), but among acidotic patients it was 33% (16/49 cases). There were 10 asymptomatic patients and none of them died as a consequence of the event. The median lactate for fatal, non-fatal and all patients was 8.3 mmol/l (IQR 7.2–13.1), 6.4 mmol/l (IQR 5.4–7.8) and 6.7 mmol/l (IQR 5.5–8.1), respectively. After adjusting for age and current CD4+ T-cell count, lactate >7 mmol/l (OR 6.27, 95% CI 1.13–34.93), blood bicarbonate <12 mmol/l (OR 10.02 relative to >18 mmol/l, 95% CI 1.33–75.65) and concurrent opportunistic infections (OR 8.69, 95% CI 1.45–52.22) were independently associated with case fatality. Blood lactate >7 mmol/l showed a sensitivity of 84% for fatality with a specificity of 60%, whereas bicarbonate <12 mmol/l showed a better specificity (85%) but a poorer sensitivity (42%). Bicarbonate <18 mmol/l appears to be as good as lactate <7 mmol/l at predicting death (sensitivity 90% and specificity 54%).
Conclusions
Our data suggest that blood lactate >7 mmol/l and blood bicarbonate <18 mmol/l appear to predict death and might help clinicians in selecting patients who may benefit from more intense monitoring.
References
1.
ImhofA., LedergerberB., GunthardH.F.Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?Clin Infect Dis2005; 41: 721–728.
2.
BolhaarM.G., KarstaedtA.S.A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis2007; 45: 254–260.
3.
BoulleA., OrrelC., KaplanR.Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther2007; 12: 753–760.
4.
GeddesR., KnightS., MoosaM.Y.A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J2006; 96: 722–724.
5.
SteadD., OslerM., BoulleA.Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa. Antivir Ther2008; 13: 937–943.
6.
CalzaL., ManfrediR., ChiodoF.Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr2005; 24: 5–15.
JohnM., MallalS.Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis2002; 15: 23–29.
11.
Arenas-PintoA., GrantA.D., EdwardsS.Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect2003; 79: 340–343.
12.
MégarbaneB., BrivetF., GuerinJ.M.Lactic acidosis and multiorgan failure secondary to antiretroviral treatments in HIV-infected patients. Presse Med1999; 28: 2257–2264.
13.
FalcóV., RodriguezD., RiberaE.Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis2002; 34: 838–846.
14.
SongaP.M., CastelnuovoB., MugashaE.B.Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis2007; 45: 514–517.
15.
ManosuthiW., PrasithsirikulW., ChumpathatN.Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. Int J Infect Dis2008; 12: 582–586.
16.
Lactic Acidosis International Study Group.Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS2007; 21: 2455–2464.
17.
CoxD.R., SnellE.J.Analysis of binary data. Boca Raton: Chapman & Hall/CRC1989.
18.
OslerM., SteadD., RebeK.Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med2010; 11: 121–129.
19.
HocquelouxL., AlbertiC., FeugeasJ.P.Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. HIV Med2003; 4: 18–23.
20.
GérardY., MaulinL., YazdanpanahY.Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS2000; 14: 2723–2730.
21.
MoyleG.J., DattaD., MandaliaS.Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS2002; 16: 1341–1349.
WohlD.A., PilcherC.D., EvansS.Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr2004; 35: 274–278.
24.
GerardY., YazdanpanahY., AjanaF.Use of stavudine is associated with a high risk of severe hyperlactataemia in black women. Antivir Ther2005; 10Suppl 3: L42–L43.
25.
SchambelanM., BensonC.A., CarrA.Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society–USA panel. J Acquir Immune Defic Syndr2002; 31: 257–275.
26.
IversL.C., MukherjeeJ.S.Point of care testing for antiretroviral therapy-related lactic acidosis in resource-poor settings. AIDS2006; 20: 779–780.
27.
MatheeS., AbrahamsM., JacksonN.Point of care lactate testing is an effective measure in supporting the WHO first-line regimen in settings with a high incidence of stavudine-related toxicity.XVI International AIDS Conference. 13–18 August 2006, Toronto, ON, Canada. Abstract MOPE0085.
